Info Sheet for Technical description

No.0013

| Organization | * Mandatoty fields |
|--------------|--------------------|
| | |

| Name of Organization* | TWOCELLS COMPANY, LIMITED | TWOCELLS COMPANY, LIMITED | | |
|---|-------------------------------------|---|--|--|
| Address, City, States, Zip, Country* | OTANI Bldg. 2F, 1-6-10 Deshio, Mina | OTANI Bldg. 2F, 1-6-10 Deshio, Minami-ku, Hiroshima City, 734-0001, Japan | | |
| URL | https://www.twocells.com/ | https://www.twocells.com/ | | |
| Brief Descriptions of Organization* (Approx. 100 words) | | We are developing allogeneic regenerative medical products using serum-free media developed in-house. We hold patents on large-scale culture of mesenchymal stem cells using serum-free media, adaptation to many diseases, and formulations. | | |
| | Name* | Masaya Matsumoto | | |
| Contact address | Department* / Position | Representative Director | | |
| | E-mail* / TEL | e-mail:matsumoto-masaya@twocells.com tell:+81-82-256-2451 | | |

| What kind of technology do you want to offer? | What kind | l of technology | do vou want to | offer? |
|---|-----------|-----------------|----------------|--------|
|---|-----------|-----------------|----------------|--------|

| | A. Clinical Development Pipelines | → Please see Sheet (A) |
|-----|--|-------------------------------|
| v v | B. Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Servicies etc. | → Please see Sheet [B] |
| | C. Platform Technologies(*) that are not included in the above (Group B) | → Please see Sheet [C] |

* Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

☑ Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

✓ Yes

□ No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

| □ Angel / Seed | (including AMED/JST grants) |
|----------------|-----------------------------|
|----------------|-----------------------------|

□ Series A

☑ Series B

□ Series C

□ Series D or further advenced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

| | Options* | Comments |
|---|----------|----------|
| V | Yes | |
| | No | |

| Filled in by* | Masaya Matsumoto | | |
|---------------|------------------|--|--|
| Date* | 23-Jul-25 | | |

Sheet [B] Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Servicies etc.

Info Sheet for Technical overview

No.B-0013

| NO.B-0013 | | | | | |
|--|-------------------------------|--|---------------------------------|--------|----------------------|
| | | | | | * Mandatoty fields |
| Title* | | | | | |
| | | <u>Regenerati</u> | ve medicine product development | | |
| Category* | | | | | |
| | Facilities | | Manufacturing equipment | | Inspection equipment |
| abla | Cells | abla | Culture medium | | Reagents |
| \square | Cell banking | | Storage / Container | | Logistics |
| | Cell / Viral vector manufactu | Cell / Viral vector manufacturing technology | | | |
| Descriptio | n* | | | | |
| We are developing regenerative medical products and their raw materials, serum-free media. We can provide clinically usable cells (without serum) and serum free media. | | | | | |
| | Filled in by* | | Masaya Mat | sumoto | |
| | _ | | · | | |
| | Date* | | 23-Jul- | -25 | |